Table 1.

Correlation between FASN expression and clinicopathological features in DLBCL patients

Patient characteristicsTotalOverexpressionReduced and/or absentP
No.%No.%No.%
No. of Patients25916262.69737.4
Age (y)
    ≤6016864.910562.56337.50.9826
    >609135.15762.63437.4
Sex
    Female10841.77973.12926.90.0026
    Male15158.38355.06845.0
Performance Status*
    0-210159.16867.33332.70.5461
    3-47040.94462.92637.1
Stage*
    I-II8952.06269.72730.30.2325
    III-IV8248.05061.03239.0
Extranodal*
    One site9555.65861.03739.00.1700
    More than one site7644.45471.02229.0
LDH (IPI)*,
    Normal (<480)8348.55262.63137.40.4470
    High (>480)8851.56068.22831.8
IPI Group*
    Low to low intermediate11466.77565.83934.20.9095
    High intermediate to high5733.33764.92035.1
GC versus ABC
    ABC20580.412259.58340.50.0122
    GC5019.63978.01122.0
p-AKT
    High (2, 3)10942.87770.63229.40.0309
    Low (0-1)14657.28457.56242.5
Ki-67
    >016262.811772.24527.8<0.0001
    ≤509637.24546.95153.1
c-Met
    Any one high18274.012870.35429.70.0002
    Both low6426.02843.83656.2
5-y overall survival75.267.30.2888
  • *IPI information was only available in 171 patients.

  • LDH categorization is based on the range of normal values in the clinical laboratory at our institution.

  • Although incidence of c-Met was 70.3%, 246 DLBCL spots were informative for both FASN and cMET expression. There were 4 DLBCL spots with cMET scores but noninformative for FASN.